-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gilead Sciences announced today that the U.
FDA Leukemia
Myelodysplastic syndrome (MDS) is a rare, often unrecognized, underdiagnosed disorder of the bone marrow that is widely recognized as a cancer
diagnostic stem cells
Magrolimab is an investigational monoclonal antibody targeting CD47, designed to interfere with the recognition of CD47 by the SIRPα receptor on macrophages, in order to block the "don't eat me" signal used by cancer cells to avoid being detected by macrophages ingest
Magrolimab is an investigational monoclonal antibody targeting CD47, designed to interfere with the recognition of CD47 by the SIRPα receptor on macrophages, in order to block the "don't eat me" signal used by cancer cells to avoid being detected by macrophages ingest
During the partial clinical pause, patients already enrolled in the affected Gilead Sciences magrolimab studies, including the pivotal Phase 3 ENHANCE study, will continue to receive treatment
Magrolimab was granted Breakthrough Therapy Designation by the FDA in 2020 for the treatment of newly diagnosed MDS
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https:// /home/20220407005786/en/FDA-Lifts-Partial-Clinical-Hold-on-MDS-and-AML-Magrolimab-Studies
